» Articles » PMID: 28895197

Impact of Cardiac Resynchronization Therapy on Mitral Valve Apparatus Geometry and Clinical Outcomes in Patients with Secondary Mitral Regurgitation

Overview
Date 2017 Sep 13
PMID 28895197
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cardiac resynchronization therapy (CRT) may improve secondary mitral regurgitation (MR) in patients with cardiomyopathy. The effects on mitral valve (MV) and left ventricular (LV) geometry, however, have not been clearly defined.

Methods: Between 2009 and 2012, 229 CRT implants were performed at a single academic center. Seventy-one had ≥mild MR at baseline and serial echocardiography, without subsequent MV intervention. The pre-CRT and follow-up echocardiograms were retrospectively reviewed for (1) MV and LV geometry measurements; (2) MR grade; and (3) LV remodeling indices.

Results: The mean age was 67 ± 15 years, and the cardiomyopathy was ischemic in 37 (52%). At a mean follow-up of 4.0 ± 1.9 years, there were significant improvements in LV ejection fraction and size, MR grade, MV tenting area and anterior leaflet tethering angle, and end-systolic interpapillary muscle distance (IPMD), and reductions in moderate-to-severe or severe MR (27% vs 15%; P = .04) and New York Heart Association functional class III/IV symptoms (83% vs 41%; P < .001). Multivariable analysis revealed the pre-CRT MV tenting height (OR 1.25, 95% CI 1.01-1.56; P = .04) and end-systolic IPMD (OR 1.14, 95% CI 0.99-1.32; P = .08) as independently associated with moderate or greater MR at follow-up. Finally, at 5 years post-CRT implantation, the estimated survival and freedom from LV assist device or cardiac transplantation was 61%.

Conclusions: CRT results in favorable effects on MV and LV geometry and decreases the prevalence of moderate-to-severe or severe MR and heart failure symptoms. The pre-CRT MV tenting height and IPMD are independently associated with persistent MR at follow-up.

Citing Articles

Treatment of Secondary Mitral Regurgitation in Heart Failure: A Shifting Paradigm in the Wake of the COAPT Trial.

Schlendorf K, OLeary J, Lindenfeld J US Cardiol. 2024; 14:e06.

PMID: 39720447 PMC: 11664767. DOI: 10.15420/usc.2020.05.


Evolution and prognosis of tricuspid and mitral regurgitation following cardiac implantable electronic devices: a systematic review and meta-analysis.

Yuyun M, Joseph J, Erqou S, Kinlay S, Echouffo-Tcheugui J, Peralta A Europace. 2024; 26(7).

PMID: 38812433 PMC: 11259857. DOI: 10.1093/europace/euae143.


The Role of False Tendons in Left Ventricular Remodeling and Secondary Mitral Regurgitation After Acute Myocardial Infarction.

Lo Presti S, Baruqui D, Perez J, Vadasseril B, Escolar E, Horvath S J Cardiovasc Imaging. 2021; 29(1):46-56.

PMID: 33511800 PMC: 7847792. DOI: 10.4250/jcvi.2020.0112.


Left ventricular wall thickness assessed by cardiac computed tomography and cardiac resynchronization therapy outcomes.

Galand V, Ghoshhajra B, Szymonifka J, Das S, Orencole M, Barre V Europace. 2019; 22(3):401-411.

PMID: 31865389 PMC: 7058969. DOI: 10.1093/europace/euz322.


Clinical manifestations, diagnosis, and treatment of ischemic mitral regurgitation: a review.

Baez-Ferrer N, Izquierdo-Gomez M, Mari-Lopez B, Montoto-Lopez J, Duque-Gomez A, Garcia-Niebla J J Thorac Dis. 2019; 10(12):6969-6986.

PMID: 30746243 PMC: 6344722. DOI: 10.21037/jtd.2018.10.64.